Inozyme Pharma announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Company’s compensation committee granted nonstatutory stock options to purchase up to an aggregate of 65,000 shares of the Company’s common stock to one new employee on December 1, 2023, at an exercise price of $3.85 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on December 1, 2023. The options have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee’s start date and 2.0833% of the shares underlying the option vesting monthly thereafter, subject to such employee’s continued service to the Company through the applicable vesting dates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INZY:
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Inozyme Pharma to Participate in Upcoming Investor Conferences
- Inozyme files $300M mixed securities shelf
- Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Inozyme reports Q3 EPS (29c), consensus (32c)